普利製藥(300630.SZ):地氯雷他定片獲得CBG上市許可
格隆匯12月18日丨普利製藥(300630.SZ)公佈,公司於近日收到荷蘭藥物評價委員會(“CBG”)簽發的地氯雷他定片的上市許可。
藥物名稱:地氯雷他定片;適應症:用於緩解慢性特發性蕁麻疹及過敏性鼻炎的相關症狀;劑型:片劑;規格:5mg。
地氯雷他定為非鎮靜性的長效三環類抗組膠藥,為氯雷他定的活性代謝物,可通過選擇性地阻斷外周H1受體,抑制各種過敏性致炎的化學介質的釋放,緩解過敏性鼻炎或慢性特發性蕁麻疹的相關症狀。地氯雷他定由Sepracor公司研製,Schering-Plough公司開發並在全球53個國家上市。地氯雷他定片2001年首次在歐洲上市;2002年在美國上市;在國內,目前地氯雷他定片已獲批進口,商品名:恩理思,規格:5mg。
公司的地氯雷他定片於2016年啟動研發,後分別遞交了歐盟和中國一致性評價補充申請,屬共線生產產品。本品2019年11月獲得中國一致性評價批准。
近日,公司獲得荷蘭藥物評價委員會所簽發的上市許可,標誌着普利製藥具備了在荷蘭銷售地氯雷他定片的資格,將對公司拓展荷蘭市場帶來積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.